Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India.

Sharma C, Wankhede S, Muralidhar S, Prakash A, Singh PK, Kathuria S, Kumar DA, Khan N, Randhawa HS, Meis JF, Chowdhary A.

Diagn Microbiol Infect Dis. 2013 May;76(1):46-50. doi: 10.1016/j.diagmicrobio.2013.02.023. Epub 2013 Mar 26.

PMID:
23537782
2.

Occurrence and characterization of Candida nivariensis from a culture collection of Candida glabrata clinical isolates in Malaysia.

Tay ST, Lotfalikhani A, Sabet NS, Ponnampalavanar S, Sulaiman S, Na SL, Ng KP.

Mycopathologia. 2014 Oct;178(3-4):307-14. doi: 10.1007/s11046-014-9778-9. Epub 2014 Jul 15.

PMID:
25022264
3.

Prevalence of Candida nivariensis and Candida bracarensis in vulvovaginal Candidiasis.

Li J, Shan Y, Fan S, Liu X.

Mycopathologia. 2014 Oct;178(3-4):279-83. doi: 10.1007/s11046-014-9800-2. Epub 2014 Aug 15.

PMID:
25118875
4.
5.

[First case report of catheter-related fungemia by Candida nivariensis in the Iberian Peninsula].

López-Soria LM, Bereciartua E, Santamaría M, Soria LM, Hernández-Almaraz JL, Mularoni A, Nieto J, Montejo M.

Rev Iberoam Micol. 2013 Jan 3;30(1):69-71. doi: 10.1016/j.riam.2012.09.001. Epub 2012 Sep 14. Spanish.

PMID:
22982698
6.

Molecular typing and in vitro fluconazole susceptibility of Candida species isolated from diabetic and nondiabetic women with vulvovaginal candidiasis in India.

Lattif AA, Mukhopadhyay G, Banerjee U, Goswami R, Prasad R.

J Microbiol Immunol Infect. 2011 Jun;44(3):166-71. doi: 10.1016/j.jmii.2011.01.020. Epub 2011 Jan 18. Erratum in: J Microbiol Immunol Infect. 2012 Oct;45(5):393. Mukhopadhyay, Gauranga [added]; Banerjee, Uma [added]; Goswami, Ravinder [added]; Prasad, Rajendra [added].

7.

First isolations in India of Candida nivariensis, a globally emerging opportunistic pathogen.

Chowdhary A, Randhawa HS, Khan ZU, Ahmad S, Juneja S, Sharma B, Roy P, Sundar G, Joseph L.

Med Mycol. 2010 Mar;48(2):416-20. doi: 10.1080/13693780903114231.

PMID:
19626545
8.

Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.

Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.

Int J Antimicrob Agents. 2008 Dec;32(6):511-4. doi: 10.1016/j.ijantimicag.2008.05.023. Epub 2008 Sep 13.

PMID:
18790613
9.

Prevalence and antifungal susceptibility patterns of new cryptic species inside the species complexes Candida parapsilosis and Candida glabrata among blood isolates from a Spanish tertiary hospital.

Miranda-Zapico I, Eraso E, Hernández-Almaraz JL, López-Soria LM, Carrillo-Muñoz AJ, Hernández-Molina JM, Quindós G.

J Antimicrob Chemother. 2011 Oct;66(10):2315-22. doi: 10.1093/jac/dkr298. Epub 2011 Jul 26.

PMID:
21795259
10.

Multidrug-resistant endemic clonal strain of Candida auris in India.

Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF.

Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):919-26. doi: 10.1007/s10096-013-2027-1. Epub 2013 Dec 20.

PMID:
24357342
11.

Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature.

Lockhart SR, Messer SA, Gherna M, Bishop JA, Merz WG, Pfaller MA, Diekema DJ.

J Clin Microbiol. 2009 Apr;47(4):1216-7. doi: 10.1128/JCM.02315-08. Epub 2009 Feb 4.

12.

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.

Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15.

13.

Multilocus sequence typing of Candida africana from patients with vulvovaginal candidiasis in New Delhi, India.

Sharma C, Muralidhar S, Xu J, Meis JF, Chowdhary A.

Mycoses. 2014 Sep;57(9):544-52. doi: 10.1111/myc.12193. Epub 2014 Apr 3.

PMID:
24697839
14.

Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginal candidiasis in southern China.

Shi XY, Yang YP, Zhang Y, Li W, Wang JD, Huang WM, Fan YM.

J Med Microbiol. 2015 Apr;64(Pt 4):390-3. doi: 10.1099/jmm.0.000024. Epub 2015 Jan 16.

PMID:
25596116
15.

Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents.

Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM.

J Clin Microbiol. 2008 Mar;46(3):933-8. doi: 10.1128/JCM.02116-07. Epub 2008 Jan 16.

16.

[In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].

Rubio Calvo MC, Gil J, Ramírez de Ocáriz I, Benito R, Rezusta A.

Rev Esp Quimioter. 2003 Jun;16(2):227-32. Spanish.

18.

Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.

Panizo MM, Reviákina V, Dolande M, Selgrad S.

Med Mycol. 2009 Mar;47(2):137-43. doi: 10.1080/13693780802144339. Epub 2008 Jun 27.

PMID:
18651308
19.

[Identification by PCR and antifungal susceptibility of vaginal clinical Candida sp isolates].

Alves IA, Camargo FP, Goulart LS.

Rev Soc Bras Med Trop. 2010 Sep-Oct;43(5):575-9. Portuguese.

20.

Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.

Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, Cornely OA, Patino H, Black TA.

Antimicrob Agents Chemother. 2009 Dec;53(12):5026-34. doi: 10.1128/AAC.01031-09. Epub 2009 Sep 28.

Supplemental Content

Support Center